DawnMed AI Empowers Full-Cycle Oncology Management: Dongman Healthcare Invites 100 Hospitals for Clinical Validation
The exponential growth of clinical data, advancements in computing hardware, and the emergence of deep learning algorithms have led to the widespread adoption of AI in healthcare. Among these areas, one field is “particularly” eager for the mature implementation of AI.
That is the field of tumor diagnosis and treatment. On one hand, tumors have always been notorious for their "high disease hazard" and "heavy disease burden." Even with coverage from medical insurance and commercial insurance, many families have suffered or are currently suffering the misfortune of falling back into poverty due to illness while facing limited survival periods. Furthermore, the trend toward younger onset ages and increasing prevalence rates for certain tumors has caused even more distress to families. Therefore, there is an urgent need within the industry to identify new technologies and therapies to prevent these tragedies.
On the other hand, further advancements in AI technology, particularly the rise of large language models in recent years, have brought hope to the industry. A growing number of Chinese companies are dedicating themselves to leveraging AI to address challenges in tumor diagnosis and the development of new therapies and drugs. One such company is Dongman (Shenzhen) Artificial Intelligence Co., Ltd. (hereinafter referred to as “Dongman Medical”), which VCBeat recently contacted.
This is a relatively young company. Its founder, Li Yingwu, is a serial entrepreneur with an interdisciplinary background spanning engineering and product management. He possesses clear insights into the internet and artificial intelligence sectors, backed by extensive industry experience. Co-founder Luo Yuze brings ten years of experience in private equity investment and has led post-investment management for multiple medical technology projects.
What appears to be an unconventional crossover, seemingly unrelated to the healthcare industry, has infused Dongman Medical with a unique DNA. The complementarity between Li Yingwu’s technological vision and Luo Yuze’s industrial resources enables Dongman Medical to both rapidly capture clinical needs and precisely design commercialization pathways.
Leveraging large language models as the foundation, develop a series of intelligent healthcare products covering the entire cycle of "diagnosis, treatment, and rehabilitation"
Dongman Medical is a high-tech enterprise specializing in AI-driven healthcare solutions. By integrating cutting-edge technologies such as deep learning, big data analytics, and medical knowledge graphs, the company develops a suite of intelligent medical products to facilitate hospitals’ smart transformation, enhance diagnostic and treatment efficiency, optimize hospital operations, and ultimately realize its vision of “universally accessible intelligent healthcare.”
Focusing on cutting-edge technologies in the healthcare sector, Dongman Medical has built a product matrix centered on intelligent diagnosis and treatment.Its core products include: DawnMed, an intelligent medical AI model developed by Dongman, based on deep learning and medical knowledge graph technologies.This model is designed to serve as an intelligent assistant for physicians, enhancing diagnostic and treatment efficiency, optimizing the decision-making process, and improving patients' healthcare experience;DM-AI-CDSS: An Intelligent Clinical Decision Support System Covering the Full Cycle of Tumor Diagnosis and Treatment, enabling the optimization of clinical pathways and the generation of precise diagnostic and treatment plans through the integration of multimodal medical data;AI-TCM-TH-CDSS System Integrating Traditional Chinese Medicine Health Preservation ConceptsIt innovatively integrates Western medical diagnostic and treatment data with Traditional Chinese Medicine (TCM) syndrome differentiation and treatment, providing patients with personalized rehabilitation and recuperation plans;Dongman Health Agent Application Platform, establishing a full-lifecycle health management service system that spans prevention, diagnosis, treatment, and follow-up.
Driven by the dual-engine strategy of “AI + Clinical Needs,” Dongman Medical has established a full-process solution covering cancer screening, precision diagnosis, intelligent decision-making, and Traditional Chinese Medicine (TCM) wellness. Currently, Dongman Medical is collaborating with leading medical institutions to advance industry-academia-research partnerships, continuously optimizing the iteration and scenario-based application of its AI products within an evidence-based medicine framework.
Among them,Dongman’s AI-powered Diagnostic and Clinical Decision Support System for Oncology, and Dongman’s AI-powered Healthcare and Wellness Clinical Decision Support System for Oncology constitute the core product portfolio that Dongman Medical currently offers to hospitals and healthcare institutions.It is evident that Dongman Medical’s product portfolio comprehensively covers both early-stage tumor diagnosis and treatment, as well as later-stage tumor rehabilitation.
In the field of oncology diagnosis and treatment, Dongman Medical has launched an intelligent tumor diagnosis and clinical decision support system. This system generates professional treatment pathways and regimens based on patient-related information, such as demographic data, clinical condition, medical imaging, and diagnostic analysis.
Dongman Tumor Intelligent Diagnostic Decision Support System (DM-AI-CDSS)
Specifically, the system possesses multimodal data processing capabilities for text, medical images, laboratory test results, and medical records, enabling in-depth analysis of medical information and the construction of a precise clinical knowledge graph, thereby laying a solid data foundation for subsequent workflows.
Furthermore, Dongman Medical has leveraged open-source model foundations such as DeepSeek to replicate OpenAI’s Deep Research and Google’s NotebookLM. Through extensive fine-tuning and specialized training, the company has developed Dawnmed (Liming Medical), an intelligent and professional vertical AI large language model tailored for the healthcare sector, which provides intelligent analytical insights to support subsequent initiatives.
「DawnMed | Liming Medical Professional Medical Model
On this basis,By integrating key clinical information such as individual tumor analysis, genetic testing, and case data, the system intelligently optimizes diagnostic and treatment pathways and assists physicians in formulating personalized comprehensive treatment strategies. Furthermore, by incorporating data on drug metabolism, drug interactions, contraindications, and individual genetic profiles, the system provides services such as drug recommendations and dosage adjustments, thereby enhancing medication safety. Meanwhile, by adapting to various disease treatment regimens and combination therapy strategies, the system ensures the safety and efficacy of personalized treatment plans, thus preventing adverse drug reactions.
As forDongman’s Intelligent Support System for Oncology Wellness (AI-TCM-TH-CDSS: AI-Assisted Decision Support System for Traditional Chinese Medicine Oncology Wellness; AI-WE-TH-CDSS: AI-Assisted Decision Support System for Western Medicine Oncology Wellness; AI-AH-CDSS: AI-Assisted Decision Support System for General Practice Community Wellness) is a comprehensive wellness support platform specifically designed for cancer rehabilitation patients and their physicians.
At present, although the necessity of implementing rehabilitation to improve survival rates and quality of life for cancer patients has become an industry consensus, and related work has been incorporated into the "Implementation Plan for Cancer Prevention and Control under the Healthy China Initiative (2023–2023)" and the "Opinions on Accelerating the Development of Rehabilitation Medical Services," as an emerging field, oncology rehabilitation inevitably faces challenges such as insufficient awareness and a lack of standards and tools.
In this regard,By integrating user health data, Dongman’s Intelligent Oncology Rehabilitation Support System provides patients with a range of personalized rehabilitation plans, including immune function enhancement, dietary regimens, exercise programs, psychological counseling, sleep optimization, and traditional Chinese medicine-based wellness care. This facilitates better health recovery for patients and enables physicians to more effectively monitor patient progress.
Additionally, according to Li Yingwu, founder of Dongman Medical, the company will deepen the integration between traditional Chinese medicine and Western medicine in health management systems in the future. This aims to achieve seamless coordination between tumor treatment decision-making and wellness management, thereby establishing a full-cycle closed loop encompassing “diagnosis, treatment, and care.”
We plan to invite one hundred institutions to participate in testing and actively seek collaborations with hospitals, physical examination centers, and insurance companies.
It is evident that Dongman Medical’s business scope has extended to broad-based health management. In fact, Dongman Medical initially started as a health management platform. And inBy integrating cutting-edge technologies such as large language models and artificial intelligence, Dongman Medical has iteratively upgraded its health management platform and launched the Dongman Health AI Agent. Individual users can access 24/7 online consultation services covering general practice, internal medicine, surgery, and psychological counseling, as well as medication purchasing and appointment registration, through the Dongman Health APP.
Dongman Health App
It is worth mentioning that,In terms of business expansion, Dongman Medical is also actively exploring the application of its AI large model system in departments such as general practice, internal medicine, surgery, gynecology, and ophthalmology, and has achieved phased results.Taking ophthalmology as an example, Dongman Medical has collected and organized a vast amount of high-quality ocular images from multiple ophthalmic medical institutions. By leveraging advanced deep learning algorithms, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), to annotate and train on these ocular images, the company has developed an ophthalmic disease recognition model with high precision and strong generalization capabilities. This model can be applied to efficient screening in ophthalmology outpatient clinics, diagnosis of complex ophthalmic diseases, and tele-ophthalmology services.
Currently, Dongman Medical has completed the prototype development of its medical AI model, DawnMed, and its oncology system products. While seeking angel-round financing, the company is also actively preparing for market promotion.
According to Luo Yuze, Co-founder and CFO of Dongman Medical, the company can collaborate with manufacturers of imaging, pathology slide, and diagnostic equipment based on its Dongman Intelligent Tumor Diagnosis and Clinical Decision Support System to create a closed loop encompassing “testing, diagnosis, and treatment planning.” It can also partner with insurance companies to empower them in identifying high-risk patients, optimizing insurance product design, improving claims processing efficiency, reducing insurance fraud risks, and enhancing treatment outcomes to lower long-term healthcare costs. Furthermore, Dongman Medical can cooperate with health check-up centers, traditional Chinese medicine practitioners, and general wellness organizations to develop customized solutions tailored to their specific needs, thereby enabling personalized health management. Additionally, the company can work with hospitals to jointly build intelligent and inclusive AI-driven hospitals.
“We will soon release the ‘DawnMed’ medical AI model and plan to invite 100 hospitals to participate in testing. Institutions interested in collaboration are welcome to contact us for discussions,” added Luo Yuze.
Looking ahead, Dongman Medical will continue to optimize the model’s multimodal data fusion capabilities, enhancing its adaptability and accuracy in handling complex cases. On this basis, Dongman Medical will make its large language model available to a broader range of physicians, including those at primary care levels, and collaborate with tertiary hospitals to conduct multicenter clinical trials. Meanwhile, the company will persistently upgrade and iterate its intelligent tumor diagnosis and clinical decision support system, as well as its intelligent oncology wellness management system. It will also continue to seek partnerships with health examination institutions and wearable device manufacturers to integrate health data interfaces, co-build an industry ecosystem, and ultimately achieve the goal of “universally accessible intelligent healthcare.”